Literature DB >> 12821496

Development and validation of a high-performance liquid chromatography assay for voriconazole.

Gennethel J Pennick1, Martin Clark, Deanna A Sutton, Michael G Rinaldi.   

Abstract

An analytical method for the determination of voriconazole (UK-109,496; Pfizer) in plasma was developed and validated. The method utilizes solid-phase extraction technology and high-performance liquid chromatography. The lower limit of quantitation is 0.2 microg/ml, and the range of linearity tested was 0.2 to 10 microg/ml.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12821496      PMCID： PMC161850          DOI： 10.1128/AAC.47.7.2348-2350.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  2 in total

1.  Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column.

Authors:  D A Stopher; R Gage
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-04-11

2.  Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors:  S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191
  2 in total
  32 in total

1.  Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.

Authors:  Maud Berge; Romain Guillemain; David A Trégouet; Catherine Amrein; Veronique Boussaud; Patrick Chevalier; Agnes Lillo-Lelouet; Christine Le Beller; Pierre Laurent-Puig; Philippe H Beaune; Eliane M Billaud; Marie-Anne Loriot
Journal:  Eur J Clin Pharmacol       Date:  2010-10-31       Impact factor: 2.953

2.  Voriconazole and fluconazole increase the exposure to oral diazepam.

Authors:  Teijo I Saari; Kari Laine; Leif Bertilsson; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-08-04       Impact factor: 2.953

3.  Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.

Authors:  I Mohammedi; M A Piens; C Padoin; D Robert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-05       Impact factor: 3.267

4.  Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum.

Authors:  GholamAli Khoschsorur; Franz Fruehwirth; Sieglinde Zelzer
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.

Authors:  Marcus J P Geist; Gerlinde Egerer; Jürgen Burhenne; Gerd Mikus
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment.

Authors:  Nilesh M Mehta; David R Halwick; Brenda L Dodson; John E Thompson; John H Arnold
Journal:  Intensive Care Med       Date:  2007-04-03       Impact factor: 17.440

7.  Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.

Authors:  Ville-Veikko Hynninen; Klaus T Olkkola; Kari Leino; Stefan Lundgren; Pertti J Neuvonen; Anders Rane; Mika Valtonen; Hanna Vyyryläinen; Kari Laine
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.

Authors:  Kathrin Kahle; Peter Langmann; Diana Schirmer; Ulrike Lenker; Daniela Keller; Annegret Helle; Hartwig Klinker; Werner J Heinz
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

9.  Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.

Authors:  Ina Scholz; Heike Oberwittler; Klaus-Dieter Riedel; Jürgen Burhenne; Johanna Weiss; Walter E Haefeli; Gerd Mikus
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

10.  Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.

Authors:  Teijo I Saari; Kari Laine; Mikko Neuvonen; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-11-07       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.